A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the effects of a single dose of the study medication in
subjects with and without hepatic impairment. 18 to 24 subjects will participate by having
multiple blood draws taken to measure the level of study medication in their blood over time.